BMS part­ners with Grit­stone on sol­id tu­mor com­bos; Roche's Alzheimer's di­ag­nos­tic gets break­through sta­tus

→ Bris­tol-My­ers Squibb $BMY is team­ing up with Emeryville, CA-based Grit­stone On­col­o­gy to try out a can­cer com­bo against sol­id tu­mors. The com­pa­nies are try­ing BMS’ Op­di­vo and Yer­voy with Grit­sone’s per­son­al­ized neoanti­gen treat­ment. They’re start­ing out test­ing the Op­di­vo com­bo in com­mon sol­id tu­mors like metasta­t­ic non-small cell lung can­cer, gas­troe­sophageal, blad­der, and col­orec­tal can­cers. They’ll al­so test Grit­stone’s drug with sys­temic Op­di­vo and a lo­cal­ized in­jec­tion of Yer­voy. Grit­sone’s pres­i­dent and CEO An­drew Allen said this in a state­ment: “The emer­gence of im­munother­a­pies in the last decade has trans­formed the way we think about treat­ing can­cer, yet there re­mains a need for new ther­a­pies, which can ini­ti­ate im­mune sys­tem recog­ni­tion of tu­mors. We have de­vel­oped our pro­grams us­ing in­sights from our pro­pri­etary tu­mor anti­gen dis­cov­ery plat­form, EDGE, to­geth­er with an im­munother­a­py plat­form which has demon­strat­ed the abil­i­ty to elic­it an en­hanced anti­gen-di­rect­ed T-cell re­sponse in pre­clin­i­cal pri­mate mod­els.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER